2. Search Result
Search Result
Results for "

Amyloid+β-Protein

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

1

Fluorescent Dyes

2

Peptides

3

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0931
    Santacruzamate A
    15+ Cited Publications

    CAY-10683

    		 HDAC Amyloid-β Neurological Disease Cancer
    Santacruzamate A (CAY-10683, STA) is a potent and selective HDAC2 inhibitor with an IC50 of 119 pM. STA also exerts neuroprotective property against amyloid-β protein fragment 25–35. STA can be used for cancer and neurological disease research .
    Santacruzamate A
  • HY-124322
    NB-360

    		Beta-secretase Amyloid-β Neurological Disease Inflammation/Immunology
    NB-360 is a potent, brain penetrable and orally active β‐secretase 1/2 (BACE1/BACE2) dual inhibitor with IC50 values of 5 and 6 nM. NB-360 can inhibit amyloid-β protein accumulation. NB-360 can be used for the researches of inflammation and neurological disease, such as Alzheimer's disease .
    NB-360
  • HY-D1443
    BSB

    (trans,trans)-1-Bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene

    		 Amyloid-β Others
    BSB is a Congo red-derived fluorescent probe. BSB binds not only to extracellular amyloid β protein, but also many intracellular lesions composed of abnormal tau and synuclein proteins. BSB acts as a prototype imaging agent for Alzheimer's disease .
    BSB
  • HY-P10040
    (Gln22)β-Amyloid (1-40) human

    		Amyloid-β Neurological Disease
    (Gln22)β-Amyloid (1-40) human is an amyloid beta protein (Aβ)-containing peptide used in Alzheimer's disease research .
    (Gln22)β-Amyloid (1-40) human
  • HY-N13742
    Dihydrohonokiol B

    Dihydrohonokiol

    		 GABA Receptor Neurological Disease
    Dihydrohonokiol B (Dihydrohonokiol) is an anxiolytic agent. Dihydrohonokiol B can reduce the neurotoxicity induced by amyloid β protein by stimulating the GABAC receptor. Dihydrohonokiol B can be used in the research of neurodegenerative diseases such as Alzheimer's disease .
    Dihydrohonokiol B
  • HY-159083
    DN5355

    		Amyloid-β Neurological Disease
    DN5355 is a small molecule compound that targets amyloid β protein (Aβ) and hyperphosphorylated tau protein. DN5355 can inhibit the aggregation of Aβ and tau protein and disaggregate the formed Aβ and tau protein fibers. DN5355 can be used in the study of Alzheimer's disease .
    DN5355
  • HY-177854
    Aβ aggregation-IN-4

    		Amyloid-β Neurological Disease
    Aβ aggregation-IN-4 can alleviate the neurotoxicity of amyloid-β protein (Aβ) and significantly reduce the level of oligomeric complexes of Aβ (Aβ-OCs). Aβ aggregation-IN-4 does not decrease the level of amyloid-β protein (Aβ). Aβ aggregation-IN-4 attenuates Aβ oligomerization and prevents oligomer-induced death of primary cortical neurons. Aβ aggregation-IN-4 can be used for the study of Alzheimer’s disease (AD) .
    Aβ aggregation-IN-4
  • HY-P10040A
    (Gln22)β-Amyloid (1-40) human TFA

    		Amyloid-β Neurological Disease
    (Gln22)β-Amyloid (1-40) (human) TFA is an amyloid beta protein (Aβ)-containing peptide used in Alzheimer's disease research .
    (Gln22)β-Amyloid (1-40) human TFA
  • HY-176439
    AChE-IN-88

    		Amyloid-β Cholinesterase (ChE) Neurological Disease
    AChE-IN-88 (Compound 26) is a novel pyridazine derivative. AChE-IN-88 is an orally active multi-target ligand for Alzheimer's disease (AD) that inhibits both acetylcholinesterase (AChE) and amyloid β protein (Aβ) aggregation (pIC50: 7.16) .
    AChE-IN-88
  • HY-N0931R
    Santacruzamate A (Standard)

    CAY-10683 (Standard)

    		 Reference Standards HDAC Amyloid-β Neurological Disease Cancer
    Santacruzamate A (Standard) is the analytical standard of Santacruzamate A. This product is intended for research and analytical applications. Santacruzamate A (CAY-10683, STA) is a potent and selective HDAC2 inhibitor with an IC50 of 119 pM. STA also exerts neuroprotective property against amyloid-β protein fragment 25–35. STA can be used for cancer and neurological disease research[1][2].
    Santacruzamate A (Standard)
  • HY-158978
    Multitarget AD inhibitor-2

    		Cholinesterase (ChE) Monoamine Oxidase Neurological Disease
    Multitarget AD inhibitor-2 (Compound VN-19) is a multitargeting inhibitor acetylcholinesterase (AChE, IC50=0.14 μM), butyrylcholinesterase (BChE, IC50=11.6 μM), monoamine oxidase B (MAO B, IC50=0.45 μM). Multitarget AD inhibitor-2 inhibits self-induced aggregation of amyloid beta protein Aβ1-42 (inhibition rate is 47.3% at 20 μM), and downregulates the level of ROS in SH-SY5Y (80 inhibition rate at 25 μM). Multitarget AD inhibitor-2 ameliorates the cognitive decline in Scopolamine (HY-N0296)-induced Alzheimer’s Disease zebrafish models .
    Multitarget AD inhibitor-2
  • HY-173282
    Aβ aggregation-IN-2

    		Amyloid-β Neurological Disease
    Aβ aggregation-IN-2 (Compound 8i) is an inhibitor of amyloid-β protein (Aβ42) aggregation, showing approximately 91% inhibition of Aβ42 aggregation at 25 μM. It also exhibits Aβ42 disaggregation effects and antioxidant activity. Aβ aggregation-IN-2 can be used for research in the field of Alzheimer's disease .
    Aβ aggregation-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: